2025 Outlook

Jeffrey Meckler, CEO of Indaptus Therapeutics, commented, "As we enter 2025, we remain committed to advancing Decoy20 through clinical trials and exploring its combination potential with BeiGene's tislelizumab. We are excited about the progress we made in 2024 and optimistic about the transformative potential of our platform to address some of the most challenging cancers."

Indaptus intends to maintain its commitment to robust data generation, with plans to share new findings at leading scientific forums as they become available, while actively pursuing opportunities to expand the applications of its Decoy platform.

The Company currently anticipates that it will achieve the following milestones in the first half of 2025:

• Launch of Combination Cohort: The Company plans to open an amendment to its clinical trial to include a combination cohort evaluating Decoy20 in conjunction with the PD-1 checkpoint inhibitor, tislelizumab.
• Expansion of Clinical Sites: Building on its progress in 2024, the Company intends to increase the number of participating clinical sites beyond the eight active locations at the end of last year, enabling broader patient enrollment.
• Higher Dose Cohort Update: The Company plans to provide an update on the patients treated in the higher dose expansion cohort, providing insights into safety and immune activation at this dose level.
• First Patient Dosed in Combination Cohort: The Company aims to start dosing the first patients in the combination cohort, marking an important step in evaluating Decoy20's synergistic potential with checkpoint inhibitors.

The company believes these milestones, if achieved, will represent significant advancements in the clinical development of Decoy20 and the broader Decoy platform.